Welcome to Novo Nordisk in the United States


Product Patents

In accordance with 35 U.S.C. § 287(a), the following table used in conjunction with the FDA-approved product labeling may be used to determine U.S. patents associated with the corresponding U.S. marketed product; additional patents may be pending in the U.S. and in other countries. The following list may not be all inclusive, and other products not listed here may be protected by one or more patents in the U.S. and additional countries.



PRODUCT

PATENT INFORMATION


FIASP® (insulin aspart recombinant)

8,324,157


GLUCAGEN® (glucagon [rDNA origin])

No unexpired patents


LEVEMIR® (insulin detemir [rDNA origin] injection)

5,750,497


NORDITROPIN® (somatropin [rDNA origin] injection)

8,841,252


NOVOEIGHT® (Antihemophilic Factor [Recombinant])

6,100,061
6,475,725
6,936,441
7,094,574
8,080,414
8,084,251
8,084,252
8,329,465
8,399,620


NOVOLIN® 70/30 (70% NPH, human insulin isophane suspension
[rDNA origin] and 30% human insulin, regular [rDNA origin])

No unexpired patents


NOVOLIN® N (insulin suspension isophane [rDNA origin])

No unexpired patents


NOVOLIN® R (insulin human [rDNA origin])

No unexpired patents


NOVOLOG® (insulin aspart [rDNA origin] injection)

No unexpired patents


NOVOLOG® MIX 70/30 (70% insulin aspart protamine suspension and 30% insulin aspart injection [rDNA origin])

No unexpired patents


NOVOSEVEN® RT (Coagulation Factor VIia [Recombinant])

8,299,029


OZEMPIC® (semaglutide)

6,899,699
7,762,994
8,114,833
8,129,343
8,536,122
8,579,869
8,672,898
8,684,969
8,920,383
9,108,002
9,132,239
9,457,154
9,486,588
9,687,611
9,775,953
RE46,363


PRANDIMET® (repaglinide/metformin HCI)

No unexpired patents


PRANDIN® (repaglinide)

No unexpired patents


REBINYN® (Coagulation Factor IX (recombinant), glycoPEGylated)

7,138,371
7,416,858
7,473,680
8,404,809
8,632,770
8,791,070


RYZODEG®70/30 (insulin degludec and insulin aspart injection)

7,615,532
6,899,699
7,762,994
8,579,869
8,672,898
8,684,969
8,920,383
9,108,002
9,132,239
9,457,154
9,486,588
9,687,611
9,775,953
RE 46,363


SAXENDA® (liraglutide [rDNA origin] injection)

6,268,343
6,458,924
7,235,627
8,114,833
8,846,618
6,899,699
7,762,994
8,579,869
8,672,898
8,684,969
8,920,383
9,108,002
9,132,239
9,457,154
9,486,588
9,687,611
9,775,953
RE 46,363


TRESIBA® (insulin degludec injection)

7,615,532
6,899,699
7,762,994
8,579,869
8,672,898
8,684,969
8,920,383
9,108,002
9,132,239
9,457,154
9,486,588
9,687,611
9,775,953
RE 46,363


TRETTEN® (Coagulation Factor XIII A-Subunit [Recombinant])

Patents pending


VAGIFEM® (estradiol vaginal tablets)

7,018,992


VICTOZA® (liraglutide [rDNA origin] injection)

6,268,343
6,458,924
7,235,627
8,114,833
8,846,618
6,899,699
7,762,994
8,579,869
8,672,898
8,684,969
8,920,383
9,108,002
9,132,239
9,457,154
9,486,588
9,687,611
9,775,953
RE 46,363


XULTOPHY® 100/3.6 (insulin degludec and liraglutide injection)

6,268,343
6,458,924
6,899,699
7,235,627
7,615,532
RE46,363
8,672,898
8,684,969
8,846,618
8,920,383
8,937,042
9,108,002
9,132,239
9,457,154
9,486,588
7,762,994
8,579,869
9,687,611
9,775,953


AUTOCOVER®

6,855,129
7,553,293
8,075,522
8,728,027


FLEXPEN®

6,004,297
RE 41,956
RE 43,834
9,265,893
7,762,994
8,579,869


FLEXPRO®

6,899,699
RE46,363
8,672,898
8,684,969
8,920,383
9,108,002
9,132,239
9,457,154
9,486,588
9,687,611
D729,730
D765,833
7,762,994
8,579,869
9,775,953

 

FLEXPRO® PENMATE®

5,980,491
6,537,252

 

FLEXTOUCH®

6,899,699
RE46,363
8,672,898
8,684,969
8,920,383
9,108,002
9,132,239
9,457,154
9,486,588
9,687,611
D724,721
D734,450
D758,571
7,762,994
8,579,869
9,775,953


NOVOFINE® 32G

6,544,238


NOVOFINE® PLUS 32G

6,544,238


NOVOPEN® ECHO®

6,248,090
6,277,098
6,663,602
7,241,278


NOVOTWIST®

7,654,986
8,137,325
8,579,869
D675,316
7,762,994


PENFILL®

No unexpired patents






© 2015 Novo Nordisk All rights reserved. 0715-00027690-1 September 2015